Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the "pan-European registry collaboration for abatacept (PANABA)

. 2017 Apr ; 36 (4) : 773-779. [epub] 20161214

Jazyk angličtina Země Německo Médium print-electronic

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/pmid27966068
Odkazy

PubMed 27966068
DOI 10.1007/s10067-016-3505-5
PII: 10.1007/s10067-016-3505-5
Knihovny.cz E-zdroje

Some evidences suggest that obesity impairs the effectiveness of TNF inhibitors. We examined the impact of body mass index (BMI) on the clinical effectiveness of abatacept in rheumatoid arthritis (RA) patients. This is a pooled analysis of 10 prospective cohorts of RA patients. All patients with available BMI were included in this study. The primary endpoint was drug retention of abatacept in the different BMI categories. Multivariable Cox regression was used to estimate hazard ratios (HRs) for drug discontinuation. A secondary endpoint was EULAR/LUNDEX response rates at 6/12 months. Of the 2015 RA patients initiating therapy with IV abatacept, 380 (18.9%) were classified as obese. Obese patients had more functional disability, and were less often RF positive. The median abatacept retention time was 1.91 years for obese RA patients compared to 2.12 years for non-obese patients (p = 0.15). The risk of abatacept discontinuation was not significantly different for overweight (HR 1.03 (95% CI 0.89-1.19)), or for obese (HR 1.08 (95% CI 0.89-1.30)) compared to normal-weight patients. Rheumatoid factor positivity reduced the risk of abatacept discontinuation (HR 0.83 (95% CI 0.72-0.95)), while previous biologic therapy was positively associated with drug interruption (HRs increasing from 1.68 to 2.16 with the line of treatments). Obese and non-obese patients attained similar rates of EULAR/LUNDEX clinical response at 6/12 months. Drug retention and clinical response rates to abatacept do not seem to be decreased by obesity in RA patients.

Zobrazit více v PubMed

Arthritis Care Res (Hoboken). 2013 Jan;65(1):122-6 PubMed

Endocrine. 2014 Dec;47(3):845-53 PubMed

Ann Rheum Dis. 2014 Nov;73(11):2029-33 PubMed

BMC Musculoskelet Disord. 2014 Jan 11;15:14 PubMed

Arthritis Rheumatol. 2016 Jun;68(6):1346-52 PubMed

Eur J Clin Invest. 2016 Dec;46(12 ):1048-1052 PubMed

Arthritis Care Res (Hoboken). 2013 Aug;65(8):1235-42 PubMed

Rheum Dis Clin North Am. 2009 Nov;35(4):745-57, vii-viii PubMed

Clin Rheumatol. 2016 Apr;35(4):857-61 PubMed

Ann Rheum Dis. 2014 Nov;73(11):1923-8 PubMed

Ann Rheum Dis. 2014 Nov;73(11):1911-3 PubMed

Rheumatology (Oxford). 2016 Feb;55(2):307-14 PubMed

Joint Bone Spine. 2015 Dec;82(6):432-6 PubMed

RMD Open. 2015 Apr 30;1(1):e000040 PubMed

Rheumatology (Oxford). 2015 Jun;54(6):1074-9 PubMed

Arthritis Care Res (Hoboken). 2013 Jan;65(1):94-100 PubMed

Ann Rheum Dis. 2014 Mar;73(3):492-509 PubMed

Arthritis Care Res (Hoboken). 2013 Jan;65(1):78-87 PubMed

Ann Rheum Dis. 2014 Nov;73(11):1914-22 PubMed

J Rheumatol. 2014 Sep;41(9):1761-5 PubMed

Arthritis Rheum. 2011 Feb;63(2):359-64 PubMed

J Clin Pharmacol. 2007 Nov;47(11):1408-20 PubMed

Ann Rheum Dis. 2008 Jun;67(6):769-74 PubMed

Arthritis Res Ther. 2011 Apr 06;13(2):104 PubMed

J Rheumatol. 2015 Apr;42(4):580-4 PubMed

Curr Drug Targets. 2010 May;11(5):586-98 PubMed

Arthritis Rheum. 2006 Feb;54(2):600-6 PubMed

Ann Rheum Dis. 2014 Nov;73(11):e74 PubMed

Arthritis Rheum. 2007 Nov;56(11):3575-82 PubMed

Joint Bone Spine. 2015 May;82(3):187-91 PubMed

Najít záznam

Citační ukazatele

Možnosti archivace